Evaluation of AppleX™ Apple Extract on Anti-Inflammatory and Healthy Aging Effects

Part of paid clinical trials in San Francisco, California.

Sponsor
Nutraland USA, Inc.
Study ID
NCT07678346
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Healthy Adult Participants
  • Healthy Aging
  • Systemic Inflammation (hsCRP)
  • Vitality

Eligibility Criteria

Sex
ALL
Age
45 Years - 70 Years
Healthy Volunteers
Accepted

Interventions

  • Apple Extract — DIETARY_SUPPLEMENT
    A whole-apple extract standardized to 15% fisetin within a natural polyphenol matrix of quercetin, chlorogenic acid, and procyanidins. Administered as a 100 mg capsule taken orally once daily with breakfast for 24 weeks.
  • Placebo — OTHER
    An identical, matching inactive look-alike capsule containing microcrystalline cellulose. Administered orally once daily with breakfast for 24 weeks.

Study Details

The goal of this clinical trial is to learn if AppleX™ Apple Extract can help lower systemic inflammation in adults aged 45-70 with signs of low-grade inflammation. It will also look at the extract's effects on fatigue, joint comfort, and biological aging metrics. The main questions it aims to answer are: * Does taking AppleX™ Apple Extract daily lower high-sensitivity C-reactive protein (hsCRP) levels, a key marker of inflammation in the blood? * Does AppleX™ Apple Extract improve participant-reported fatigue and joint comfort? * Does the extract slow down biological or epigenetic aging metrics compared to a placebo? Researchers will compare AppleX™ Apple Extract to a placebo (a look-alike capsule that contains no active ingredients) to see if the apple extract has a measurable anti-inflammatory and healthy aging effect.

Key Dates

Start date
Jul 31, 2026
Status verified
Jun 2026
Primary completion
Jan 31, 2027
Completion
Feb 28, 2027

Study Design

Enrollment
70 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: AppleX™ Group
    100 mg whole-apple extract capsule standardized to 15% fisetin, taken once daily with breakfast for 24 weeks.
  • Placebo Comparator: Placebo
    An identical look-alike microcrystalline cellulose capsule, taken once daily with breakfast for 24 weeks

Primary Outcome Measure

Change from Baseline in High-Sensitivity C-Reactive Protein (hsCRP) at Week 24 [ Time Frame: Baseline (Week 0) and Week 24 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Alethios, Inc.San FranciscoCalifornia94109
Zeenia Framroze, BA MPhil
[email protected]
650-206-8006

Find similar trials in San Francisco, CA

By research site
Alethios, Inc.· San Francisco, CA

Related Studies